Filtered By:
Condition: Atrial Fibrillation
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 563 results found since Jan 2013.

From cryptogenic to ESUS: Toward precision medicine?
Rev Neurol (Paris). 2022 May 18:S0035-3787(22)00592-6. doi: 10.1016/j.neurol.2022.01.016. Online ahead of print.ABSTRACTCryptogenic infarctions are infarctions without a defined cause, despite a complete work-up. They differ from infarctions of undetermined causes, which may involve overlapping causes or an incomplete investigation. It is also different from uncommon heritable and non-heritable causes. The term embolic stroke of undetermined source (ESUS) proposed in 2014 is defined as a non-lacunar brain infarct without proximal arterial stenosis or cardioembolic sources. The major advantage of this definition compared to...
Source: Revue Neurologique - May 21, 2022 Category: Neurology Authors: S Timsit Source Type: research

Atrial Fibrillation and Thrombosis: The Missing Molecular Links ⁎ ⁎
Nonvalvular atrial fibrillation (AF) confers a 5-fold increased risk of stroke and systemic thromboembolism (TE), especially in the presence of stroke risk factors (1). AF is common, and the TE manifestations are evident in many diverse cardiovascular conditions. For example, transient new-onset AF in acute myocardial infarction is a risk factor for stroke (2). Also, patients with left ventricular systolic impairment with associated AF are at high risk of TE (3). Fortunately, the use of anticoagulation therapy reduces the risk of stroke and/or TE (by 64%) as well as all-cause mortality (by 26%), whereas aspirin results in ...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 18, 2013 Category: Cardiology Source Type: research

Atrial Fibrillation and Thrombosis: The Missing Molecular Links⁎
Nonvalvular atrial fibrillation (AF) confers a 5-fold increased risk of stroke and systemic thromboembolism (TE), especially in the presence of stroke risk factors (). AF is common, and the TE manifestations are evident in many diverse cardiovascular conditions. For example, transient new-onset AF in acute myocardial infarction is a risk factor for stroke (). Also, patients with left ventricular systolic impairment with associated AF are at high risk of TE (). Fortunately, the use of anticoagulation therapy reduces the risk of stroke and/or TE (by 64%) as well as all-cause mortality (by 26%), whereas aspirin results in a n...
Source: Journal of the American College of Cardiology - January 21, 2013 Category: Cardiology Authors: Andrew D. Blann, Gregory Y.H. Lip Tags: Heart Rhythm Disorders: Editorial Comment Source Type: research

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice
Atrial fibrillation, the commonest cardiac arrhythmia, predisposes to thrombus formation and consequently increases risk of ischaemic stroke. Recent years have seen approval of a number of novel oral anticoagulants. Nevertheless, warfarin and aspirin remain the mainstays of therapy. It is widely appreciated that both these agents increase the likelihood of bleeding: there is a popular conception that this risk is greater with warfarin. In fact, well-managed warfarin therapy (INR 2-3) has little effect on bleeding risk and is twice as effective as aspirin at preventing stroke. Patients with atrial fibrillation and a further...
Source: Postgraduate Medical Journal - May 17, 2013 Category: Journals (General) Authors: Sabir, I. N., Matthews, G. D. K., Huang, C. L.-H. Tags: Open access Reviews Source Type: research

Antithrombotic Therapy for Prevention of Various Thrombotic Diseases
Abstract The majority of sudden onset serious diseases, such as acute myocardial infarction, ischemic stroke, and pulmonary embolism, are thrombotic diseases. Antithrombotic therapy in general has a potential to reduce the risk of thrombotic diseases, though it increases the risk of serious bleeding events. Of the various antithrombotic agents currently available, the antiplatelet agent aspirin and the anticoagulant agent warfarin have the most robust clinical evidence. Aspirin reduces the risk of cardiovascular (CV) death, recurrence of myocardial infarction and ischemic stroke by up to 25%. Aspirin is an establish...
Source: Drug Development Research - November 15, 2013 Category: Drugs & Pharmacology Authors: Shinya Goto, Aiko Tomita Tags: Clinical Overview Source Type: research

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
Conclusion Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use.
Source: European Heart Journal - January 21, 2014 Category: Cardiology Authors: Alexander, J. H., Lopes, R. D., Thomas, L., Alings, M., Atar, D., Aylward, P., Goto, S., Hanna, M., Huber, K., Husted, S., Lewis, B. S., McMurray, J. J. V., Pais, P., Pouleur, H., Steg, P. G., Verheugt, F. W. A., Wojdyla, D. M., Granger, C. B., Wallentin, Tags: Atrial fibrillation Source Type: research

Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study
Conclusions This hypothesis-generating pilot trial has found that TEE may be used for refinement of stroke risk in paroxysmal atrial fibrillation patients. A larger trial is needed to confirm these data. (ClinicalTrials.gov number NTC00224757).
Source: Heart - March 5, 2014 Category: Cardiology Authors: Dinh, T., Baur, L. H. B., Pisters, R., Kamp, O., Verheugt, F. W. A., Smeets, J. L. R. M., Cheriex, E. C., Lindeboom, J.-E., Heesen, W. F., Tieleman, R. G., Prins, M. H., Crijns, H. J. G. M., for the TIARA investigators, Dinh, Pisters, Tieleman, Prins, Cri Tags: Drugs: cardiovascular system, Echocardiography, Clinical diagnostic tests, Epidemiology Cardiac risk factors and prevention Source Type: research

Abstract 264: Assessing Thromboembolic Risk In Patients Undergoing Direct Electrical Cardioversion Within 48 Hours After Onset Of Atrial Fibrillation Session Title: Poster Session II
Conclusions In patients with acute onset atrial fibrillation, odds of thromboembolic complications are over 5 times higher in patients who did not receive therapeutic anti-coagulation at the time of DCC, despite having a lower baseline stroke risk as defined by their CHA2DS2-VASc scores. In addition, the two patients in our study who did have a stroke in the therapeutically anti-coagulated group had ceased their anticoagulant prior to the stroke.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Garg, A., Khunger, M., Seicean, S., Chung, M., Tchou, P. Tags: Session Title: Poster Session II Source Type: research

The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes
Rivaroxaban, a direct factor Xa inhibitor, is a novel oral anticoagulant approved for stroke prevention in patients with nonvalvular atrial fibrillation and also approved in Europe (but not in the United States) to prevent recurrent ischemic events in patients with recent acute coronary syndromes. Advantages of rivaroxaban over oral anticoagulants such as warfarin are the lack of need for ongoing monitoring, a fixed-dose regimen, and fewer drug and food interactions. Drawbacks include a lack of an antidote and the absence of a widely available method to reliably monitor the anticoagulant effect. In patients at risk of stro...
Source: Journal of Cardiovascular Pharmacology and Therapeutics - October 15, 2014 Category: Cardiology Authors: Reddy, P., Giugliano, R. P. Tags: Reviews Source Type: research

Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure
Conclusions LAA closure with an occlusion device in patients contraindicated for oral anticoagulants is a therapeutic option associated with fewer thromboembolic and haemorrhagic events than expected from risk scores, particularly in the second year postimplantation.
Source: Heart - May 12, 2015 Category: Cardiology Authors: Minguez, J. R. L., Asensio, J. M. N., Gragera, J. E., Costa, M., Gonzalez, I. C., de Carlos, F. G., Diaz, J. A. F., Yuste, V. M., Gonzalez, R. M., Dominguez-Franco, A., Buendia, A. B., Garibi, J. H., Hernandez, F. H., Ribeiro, V. G. Tags: Congenital heart disease in adult patients, Editor's choice, Drugs: cardiovascular system, Heart failure, Hypertension, Epidemiology Arrhythmias and sudden death Source Type: research

Abstract 150: Antithrombotic Use in Nonvalvular Atrial Fibrillation (NVAF): Alignment between Guidelines and Emerging Evidence with Clinician Prescribing Preferences Session Title: Poster Session I
Conclusions: Similar to findings from indirect treatment comparison studies, physicians largely prefer NOACs_particularly apixaban_compared to warfarin or aspirin for stroke risk reduction in NVAF patients. Additional research is needed to determine why NOACs are underused in practice.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Shafrin, J., Bruno, A., MacEwan, J. P., Campinha-Bacote, A., Trocio, J., Tan, W., Romley, J. A. Tags: Session Title: Poster Session I Source Type: research

Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin
Conclusions This analysis demonstrates that LAAC with the Watchman device is a cost-effective and cost-saving solution for stroke risk reduction in patients with non-valvular AF who are at risk for stroke but have contraindications to warfarin.
Source: Europace - June 28, 2016 Category: Cardiology Authors: Reddy, V. Y., Akehurst, R. L., Armstrong, S. O., Amorosi, S. L., Brereton, N., Hertz, D. S., Holmes, D. R. Tags: Atrial fibrillation Source Type: research

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation
Conclusion Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials. Left atrial appendage closure in both settings achieves cost parity in a relatively short period of time and may offer substantial savings compared with current therapies. Savings are most pronounced among higher risk patients and those unsuitable for anticoagulation.
Source: European Heart Journal - December 29, 2016 Category: Cardiology Authors: Panikker, S., Lord, J., Jarman, J. W. E., Armstrong, S., Jones, D. G., Haldar, S., Butcher, C., Khan, H., Mantziari, L., Nicol, E., Hussain, W., Clague, J. R., Foran, J. P., Markides, V., Wong, T. Tags: Thrombosis and antithrombotic therapy Source Type: research

Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
Publication date: Available online 24 April 2017 Source:American Heart Journal Author(s): Renato D. Lopes, Marco Alings, Stuart J. Connolly, Heather Beresh, Christopher B. Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens C. Nielsen, David Conen, Stefan H. Hohnloser, Georges H. Mairesse, Philippe Mabo, A. John Camm, Jeffrey S. Healey Device-detected subclinical atrial fibrillation (AF) refers to infrequent, short-lasting, asymptomatic AF that is detected only with long-term continuous monitoring. Subclinical AF is common and associated with an increased risk of stroke; however, the risk of stroke with subclinical AF ...
Source: American Heart Journal - April 24, 2017 Category: Cardiology Source Type: research